Wednesday, April 8, 2026
← Back to archivePolicy
Policy•KFF•Apr 7, 2026
Tracking Key Mental Health and Substance Use Policy Actions Under the Trump Administration
background ▾
- •Trump administration shifting mental health/substance use policy from access-expansion to law-and-order approach, reversing Biden-era priorities and affecting federal infrastructure including SAMHSA reorganization
- •Concurrent continuation of some treatment initiatives (SUPPORT Act reauthorization) alongside scaling back of federal grants and programs, creating policy uncertainty for providers and payers
- •Monitor implementation of HALT Act, SAMHSA restructuring proposals, and impact on opioid treatment access and mental health service delivery to insured and vulnerable populations already facing significant barriers
Policy•KFF•Apr 7, 2026
Measles Elimination Status: What It Is and How the U.S. Could Lose It
background ▾
- •Measles elimination status is at imminent risk due to 3,800+ cases in 15 months and vaccination coverage below the 95% herd immunity threshold, with national two-dose MMR coverage at only 92.5% for 2024 kindergarten entrants
- •Public health infrastructure collapse—driven by funding/staffing cuts at federal, state, and local levels combined with contradictory messaging from HHS Secretary Robert F. Kennedy Jr. and absence of Senate-confirmed CDC leadership—has crippled outbreak response capacity
- •Vaccine hesitancy fueled by safety skepticism and eroded health authority trust poses ongoing challenge; loss of elimination status would mark a watershed moment in U.S. public health policy and vaccine confidence with long-term consequences for disease control
MMR vaccinemeasles-mumps-rubella vaccine
→ Read original articlePolicy•Fierce Pharma•Apr 7, 2026
FDA seeks legislative teeth to bite back against misleading DTC drug ads
background ▾
- •FDA is seeking statutory authority to deem drugs misbranded based on DTC ad content—a major expansion of regulatory power that would streamline enforcement beyond current warning letter approaches.
- •Proposed legislation would mandate conspicuous FDA non-approval disclosures for compounded drugs and prohibit unsubstantiated efficacy claims, directly responding to the GLP-1 compounding boom.
- •Congressional passage is required but uncertain; if enacted, this would materially increase compliance costs and legal risk for companies with aggressive DTC campaigns and compounded drug portfolios.
Bristol Myers SquibbEli LillyNovartisOzempic
→ Read original articleMarket Access
Market Access•Fierce Pharma•Apr 7, 2026
Vertex taps Halozyme and its recently acquired Elektrofi tech in $15M drug delivery deal
background ▾
- •Halozyme's $750 million Elektrofi acquisition is generating near-term commercial validation, with Vertex's $15 million licensing deal demonstrating market demand for hyperconcentration delivery technology within months of acquisition close
- •Vertex's focus on small-volume, patient-administered biologics signals strategic commitment to convenient dosing; industry-wide shift toward subcutaneous and home-based delivery is intensifying with parallel deals from Biogen, GSK, and others
- •Monitor: regulatory pathways for Vertex's three undisclosed programs; Halozyme's ability to replicate this licensing model with other partners; ongoing patent dispute between Halozyme and Merck over hyaluronidase technology in Keytruda formulation
Vertex PharmaceuticalsHalozymeElektrofiHyperconEnhanzeHybrozyme
→ Read original articleMarket Access•Fierce Pharma•Apr 7, 2026
Ardena’s US plant buy pays off as CDMO endures rough geopolitical waters
background ▾
- •Ardena's focused strategy on nanomedicines (100+ programs managed, 30 in clinic) and advanced oral solids differentiates it in a CDMO market where clients demand speed and integration for accelerated regulatory pathways
- •The company's purpose-built Dutch nanomedicine facility is generating strong international demand despite geopolitical headwinds, suggesting specialized capabilities can transcend supply chain and trade barriers
- •Watch for pipeline outcomes among Ardena's 30 active nanomedicine programs and whether biotech adoption of AI-accelerated development drives further consolidation of CDMO partnerships around specialized platforms
ArdenaNanologica
→ Read original articleMarket Access•Fierce Biotech•Apr 8, 2026
With 3 acquisitions to digest, Gilead shifts focus from M&A to pipeline that has 'never been stronger'
background ▾
- •Gilead has deployed ~$12.6B in three transformational acquisitions over six weeks, signaling a deliberate bet on cell therapy, bispecific antibodies, and ADCs as core growth engines.
- •Ouro's OM336 (gamgertamig) is positioned as a "pipeline-in-a-product" with potential to treat multiple B-cell and plasma-cell driven autoimmune diseases; registrational trial planned for 2027.
- •Tubulis' proprietary ADC linkers (P5 and Alco5) enable novel payloads; Gilead sees potential for TUB-040 in ovarian cancer alone to justify the $3.15B upfront investment.
Gilead SciencesArcellxOuro Medicinesanito-celOM336gamgertamig
→ Read original articleMarket Access•Fierce Biotech•Apr 7, 2026
E2 lands $80M series C for next-gen thrombectomy treatment
background ▾
- •E2's Hēlo platform achieved FDA clearance for pulmonary embolism treatment with a novel dual-action mechanism (aspiration + mechanical disruption), differentiating it from existing mechanical thrombectomy systems
- •The $80M Series C, oversubscribed and co-led by top-tier medtech investors, validates market demand and E2's commercial potential despite competitive crowding from Stryker, Boston Scientific, and other entrants
- •Watch for E2's commercial execution metrics (hospital adoption, pricing strategy, clinical evidence generation) and competitive response from Stryker/Boston Scientific; potential acquisition target given strong technology and investor backing
E2 (Endovascular Engineering)Gilde HealthcareNorwestHēlo Thrombectomy PlatformFlowTriever
→ Read original articleMarket Access•Fierce Biotech•Apr 7, 2026
Gilead pays $3.1B upfront for Tubulis to bolster oncology ADC pipeline
background ▾
- •Gilead is aggressively consolidating ADC capabilities through a $3.15B acquisition of Tubulis, signaling confidence in NaPi2b-targeted TUB-040 as a differentiated oncology asset after competitors abandoned the target.
- •TUB-040 showed 59% ORR in platinum-resistant ovarian cancer with apparent tolerability advantages, but historical failures of competing NaPi2b-ADCs create execution risk in pivotal development.
- •Watch for TUB-040 IND/pivotal trial initiation timelines and interim efficacy/safety data; also monitor whether Gilead's three recent mega-acquisitions ($12.6B+ combined) reflect strategic strength or portfolio desperation.
Gilead SciencesTubulisBristol Myers SquibbTUB-040Trodelvy
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Apr 7, 2026
Lilly pays AC Immune $12.5M to expand Alzheimer’s collab as asset draws closer to clinic
background ▾
- •AC Immune's morphomer tau inhibitor is imminently entering IND-enabling studies, positioning it to enter human trials in the near term as part of the expanded Lilly collaboration
- •AC Immune's recent 30% workforce reduction and deprioritization of non-Alzheimer's programs (morADC, ASC, TDP-43) suggest internal resource constraints and shifting confidence in broader morphomer applications
- •Monitor phase 1 initiation timeline and safety/tolerability profile; also track competing tau-targeting programs including J&J's paused phase 2b anti-tau immunotherapy for enrollment and efficacy signals
Eli LillyAC ImmuneJohnson & Johnsonmorphomer small-molecule (tau aggregation inhibitor - preclinical)ACI-7104.056 (Parkinson's disease - phase 2)
→ Read original article